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 Abstract. 
The lung pathology seen in patients with COVID-19 shows significant 
microvascular thrombosis and haemorrhage linked to extensive alveolar and 
interstitial inflammation, which shares features with macrophage activation 
syndrome (MAS). We have termed the lung-restricted vascular immunopathology 
associated with COVID-19 as diffuse pulmonary intravascular coagulopathy 
(PIC), which is distinct from disseminated intravascular coagulation (DIC) in its 
early stages. Raised D-dimers and cardiac enzymes— r pectfully reflecting 
pulmonary vascular bed thrombosis with fibrinolysis and emergent pulmonary 
hypertension-induced ventricular stress—in the face of normal fibrinogen and 
platelet levels, are key early features of severe COVID-19-related PIC. Extensive 
immunothrombosis over a wide pulmonary vascular territory with lack of 
confirmation of COVID-19 viraemia in early disease best  explains the adverse 
impact of male sex, hypertension, obesity and diabetes on the prognosis of 
patients with COVID-19. The immune mechanisms that underlie diffuse alveolar 
and pulmonary insterstitial inflammation in COVID-19 includes a MAS-like state 
that triggers extensive immunothrombosis, which might unmask subclinical 
cardiovascular disease and is distinct from the MAS and DIC that is familiar to 
rheumatologists.    
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Introduction 
The COVID-19 pneumonia pandemic and earlier coronavirus outbreaks have been associated 
with adult respiratory distress syndrome (ARDS) and a worse outcome in older subjects than 
in younger ones.1,2  The severity of the systemic inflammation in response to the human 
coronavirus family members has features reminiscent of a cytokine storm or macrophage 
activation syndrome (MAS), also known as secondary haemophagocytic lymphohistocytosis 
(HLH).3,4 This has inspired use of directed anti-cytokine therapy strategies for severe 
COVID-19 pneumonia, as these agents are known to be useful in MAS spectrum disease4,5. A 
key feature of HLH/MAS is haemophagocytosis and an acute consumptive coagulopathy 
leading to disseminated intravascular coagulation (DIC), which has also been reported in  
COVID-19 pneumonia, but usually as a pre-terminal event.6,7 Indeed,  the hypercytokinaemia 
with extreme hyperferritinaemia that is typically seen with viral HLH is evident in some 
patients with COVID-19 pneumonia.8 
 
COVID-19 Pneumonia is distinct from Macrophage Activation Syndrome 
We recently described how the MAS-like pulmonary immunopathology characteristic of 
COVID-19 pneumonia is distinct from classical HLH.9 aemphagocytosis is a cardinal 
feature of MAS,10,11 and has also been reported in SARS.12,13 In SARS, this process might 
involve phagocytosis of extravascular red blood cells consequent to severe lung micro-
vascular damage, micro-haemorrhage with physiological haemophagocytosis of extravascular 
red blood cells (Figure 1B), or possibly very advanced disease with frank MAS-like 
pathology and DIC (Figure 1).  The hypercytokinameia of MAS/HLH is often associated 
with extremely high serum ferritin concentrations (10,000 - 100,000 ng/mL or higher), 
whereas in patients with COVID-19, serum ferritin concentrations are typically in the 500 - 
3,000 ng/mL range, at least early in the illness. Another clear distinguishing feature between 
COVID-19 pneumonia and MAS/HLH is the liver function derangement that is 
characteristically seen in MAS/HLH and can contribute to coagulopathy secondary to loss of 
liver syntethic function (Figure 1). 
 
Extensive lung infiltration by macrophages and other immune cells has been reported in 
SARS pneumonia, with similar findings emerging in patients with COVID-19 pneumonia,13-
16 leading to diffuse alveolar damage. The extensive nature of SARS-CoV-2 viral infection 
results in diffuse inflammation that involves the large juxtaposed pulmonary vascular 
network,17 and this diffuse, slowly evolving COVID-19 pneumonia has similarities to a 
MAS-like clinical and laboratory picture. These clinical findings suggested to us that an 
initial pulmonary intravascular coagulopathy (PIC) occurs in patients with COVID-19 
pneumonia that is distinct from DIC.17 Herein, we propose a model for the pathophysiology 
of this PIC and describe how extensive coronavirus infection and age-related changes in 
immunity, combined with diffuse pulmonary immunothrombosis, explains the cardiovascular 
mortality in these patients (Table 1).  
   
 
Pulmonary Vascular Pathology Patterns in SARS and COVID-19 
Acute respiratory infections are associated with a higher risk of cardiovascular related death, 
especially in the weeks immediately after infection, and particularly in older patients, and 
those with pre-existing cardiovascular disease. Severity of pneumonia in these patients is 
linked to an increased risk of death.18,19 Of particular note, one pathological study 
demonstrated similar vascular changes in post-mortem tissue obtained from subjects 
succumbing to non-SARS-related bronchopneumonia as in those who died from SARS,20 
indicating that vascular thrombosis triggered by infection, rather than the infection itself, may 
be key (Figure 2).  
 
Coronavirus family members show tropism for ACE2 on type II pneumocytes. This tropism, 
along with the close anatomical juxtaposition of type II pneumocytes and  the pulmonary 
vascular network and severe, multifaceted inflammatory reactions, likely drives the 
generalised pulmonary hypercoagulable state in a pneumocyte-interstitium-pulmonary 
endothelium-small pulmonary vessel axis17,21 (Figure 2). It has recently emerged from single 
cell sequencing analysis that the vast majority of pulmonary ACE2 gene expression is 
confined to a small population of type II pneumocytes and is largely excluded from 
endothelial cells and alveolar macrophages.22 From a clinical perspective, diffuse alveolar 
changes (determined by CT scan) are distinct from bronchopneumonia and show how 
COVID-19 interfaces with a large area of the pulmonary microvasculature. This likely 
explains the propensity for diffuse pathology in patients with COVID-19 pneumonia. Indeed, 
extensive air space changes on CT associate with a worse prognosis in patients with COVID-
19 pneumonia;23 indeed diffuse disease on CT is also a feature of subjects who succumbed to 
SARS infections (Figure 2).24 
 
ACE2 has been shown to regulate innate immunity and, in mice, genetic deletion of Ace2 
leads to more severe pulmonary inflammation after acid inhiliation.25 These findings suggest 
that ACE2 downregulation could aggravate extensive inflammation over a wide alveolar-
capillary network. Indeed it was subsequently shown that injecting the SARS spike protein in 
mice leads to similar lung pathology, likely due to internalisaiton of the Ace2 receptor and 
subsequent inhibition of Ace-2-mediated generation of the immunoregulatory angiotensin 1-7 
peptide, which signals via the Mas receptor.24 Ace2 deficiency was also associated with a 
more severe pneumonitis and a higher mortality in a mouse model of influenza infection.25 
Theoretically, a similar mechanism could increase the proclivity towards immunothrombosis 
in man. In humans, the MERS coronavirus principally uses the DPP4 receptor, which is not 
restricted to type II pneumocytes; this virus results in clinical features and pathology similar 
to SARS and SARS-CoV-2, including a high mortality rate.26  Analogous to ACE2, in some 
experimental systems the DPP4 receptor may negatively regulate lymphocyte function, which 
could point to shared coronavirus mechanism contributing to PIC (Table 3) 27. 
 
Pulmonary Vascular Disease in SARS and COVID-19 
The SARS-CoV-2 and SARS virus genomes are highly homologous and patients infected 
with these viruses appear to share common clinical and pathological features.28,29 Initial post-
mortem reports from three SARS cases indicated diffuse alveolar damage and small 
pulmonary vessel thrombosis and haemorrhage, but also a more generalised small vessel 
thrombosis;30 a second study of 6 cases reported vascular pathology in 2 cases.13 A later 
study of pathological specimens from 20 patients with SARS confirmed the presence of 
diffuse alveolar damage but also noted fibrin thrombi, small vessel occlusion, and pulmonary 
infarction in upwards of 80% of cases.20 A review of aggregated SARS pathology reports 
shows evidence for vessel wall oedema, inflammatory cell infiltration into the walls of the 
pulmonary microvasculature, significant haemorrhagic necrosis, and vessel microthrombus 
mostly confined to the lung and pulmonary tissue infarction, in the context of septal 
inflammation and diffuse alveolar damage.31 Limited data have emerged from patients with 
COVID-19 pneumonia, and these data paint a similar pulmonary vascular picture with blood 
vessel wall oedema, modest vessel wall immune cell infiltration, hyaline thrombosis, 
haemorrhagic change and infarction.15,32,33 Emergent data have also emphasised prominent 
capillary thrombosis,33 and one study also reported cardiomegaly and right ventricular 
dilatation, pointing toward the expected development of pulmonary artery hypertension.31  
 
 
Lack of Evidence for Coronavirus Myocarditis or Coronary Vasculitis  
Myocarditis may occur after severe respiratory viral pneumonia; this is relatively rare but 
well documented, especially in younger females following influenza infection (Table 2).  
Understandably, raised cardiac enzymes in patients with COVID-19 have been taken to 
potentially represent myocarditis or virus-associated cardiac vasculitis. In SARS virus 
infection, most evidence points away from cardiac involvement.34,35 The ACE2 receptor is 
also expressed on endothelial cells, and one in situ hybridisation study suggested that 
pulmonary endothelial cells are infected.36  Other studies showed a complete absence or very 
low level of potential endothelial cell infection.34,35 Moreover, another study in patients with 
SARS suggested a close link between infection of pneumocytes and inflammatory cytokine 
expression in the same cells,37 but this was not reported for endothelium. Recent publications 
indicate that SARS-CoV-2 RNA was undetectable in the blood39 r was detected in only 15% 
of cases,40 again arguing for a pathology centred around pneumocytes and adjacent tissue 
pathology rather than systemic viral infection (figure 2).38,39 
 
A role for the ACE2 receptor in cardiovascular biology predates the link between pulmonary 
pathology and COVID-19 pneumonia. Genetic deletion of ACE2 in rodents was associated 
with ventricular contractility defects but no evidenc  of cardiomyopathy or fibrosis.40 The 
link between ACE2 downregulation in lung tissue, either in genetically manipulated mice or 
mice treated with SARS-spike protein, and increased inflammation suggests a relatively 
simple model whereby coronavirus infection of ACE2-expressing cardiomyocytes or cardiac 
endothelium may trigger a similar inflammatory pathology. In the most comprehensive study 
of cardiac involvement in patients that succumbed to SARS, viral RNA was detectable in a 
third of post-morten cardiac tissues and was associated with decreased ACE2 expression and 
increased macrophage infiltration.41 The same study showed no evidence of myocyte necrosis 
or lymphocytic infiltration, both hallmarks of viral myocarditis42.  Overall autopsy reports, 
including those emerging in COVID-19, vary from showing no significant pathology, 
infiltrating macrophages, and some reports of occasional infiltrating CD4+ T cells33.  
The cardiac pathology in  SARS-Cov-2 pneumonia needs evaluation in the light of known 
cardiovascular comorbidities including hypertension and PIC and the MAS-like state with 
associated hypoxaemia and secondary pulmonary artery hypertension.  The 
hypercytokinaemia that is part of the MAS-like state and is independent of viraemia may also 
influence ACE2 tissue expression. One key cytokine characteristic of MAS-like pathology, 
IFNけ, has been shown to downregulate ACE2 expression on am epithelial cell line, but this 
has not been reported for heart cells.43  Therfore, reported changes in the heart tissue 
including endothelium could represent a cytokine and hypoxia effect rather than viral 
infection.  
 
 
Laboratory data point towards early Pulmonary Intravascular Coagulopathy 
The key early laboratory observations i  patients with COVID-19 pneumonia are an elevated 
plasma D-dimer concentration in conjunction with elevated cardiac markers, including brain 
natriuretic peptide, creatinine kinase, and troponin-T; elevation of the latter at hospitalisation 
is linked to a poor prognosis.44 In keeping with this, a previous study has reported that 
elevated plasma levels of fibrin degradation products, including D-dimers, constitutes a 
significant independent biomarker of poor prognosis.6 For example, Zhou and colleagues 
reported that 90% of patients presenting with COVID-19 had increased activation of 
coagulation, as indicated by elevated D-dimer concentrations at presentation.23 Importantly, 
D-dimer concentrations above 1g/ml were associated with an 18-fold increased odds ratio 
for fatal outcome.23 Furthermore, progressive elevation of D-dimer and fibrin degradation 
products were seen in non-survivors.23  However, despite this increase in D-dimers, patients 
with COVID-19 do not typically develop overt systemic DIC. In rare cases of COVID-19 in 
which overt DIC does develop, it tends to be restricted to late-stage disease. This is reflected 
in the consistent observation that platelet counts and fibrinogen concentration are not 
significantly reduced in patients with COVID-19 despite marked increases in D-dimer 
concentrations45. Indeed, fibrinogen generally remained elevated in these patients, in keeping 
with an ongoing acute phase response.  
 
Extensive Pulmonary Inflammation and thrombosis in COVID-19 Pathology 
As mentioned, severe COVID-19 sepsis is associated with a marked MAS-type picture with 
increased inflammatory markers and ferritin concentrations that undoubtedly results in local 
activation of pulmonary vasculature endothelial cells. For example, interleukin (IL)-1, IL-6 
and TNF have all been shown to trigger acute endothelial cell activation.46 Given the critical 
roles played by endothelial cells in maintaining normal haemostasis, regulating fibrinolysis, 
and determining vessel wall permeability, local endothelial cell dysfunction in the pulmonary 
microvasculature is likely to play an important role in the thrombo-inflammatory processes 
that ultimately results in COVID-19 vasculopathy, V/Q mismatch, and a clinical phenotype 
of refractory ARDS.  
 
In addition, the MAS-like picture associated with COVID-19 pneumonia will trigger 
expression of active tissue factor on endothelial cells and activated infiltrating macrophages 
and neutrophils.46 The net effect will be local presentation of blood-borne tissue factor within 
the lungs, which will further amplify activation of the coagulation cascade. Importantly, 
endothelial cell disruption, tissue factor expression, and activation of the coagulation cascade 
activation will all be progressively exacerbated by development of local hypoxia,47 
establishing a deleterious positive thrombo-inflammatory feedback loop within the small 
vessels of the lungs with thrombosis and haemorrhage (figure 3). Beyond these coagulopathic 
changes occurring within the pulmonary vasculature, previous studies of broncoalveolar 
lavage have shown that both severe pneumonia and ARDS are associated with enhanced 
thrombin generation and fibrin deposition within the bronchoalveolar system.48 These 
changes correlate with severity of inflammation49 and are primarily driven by upregulation of 
tissue factor expression within the alveoli, coupled with a reduction in fibrinolysis induced by 
plasminogen activation inhibitor-1.50 The biological mechanisms responsible for the 
extremely elevated plasma D-dimer concentrations in patients with severe COVID-19, 
together with the marked inter-individual variations observed, remain unclear. Nonetheless, 
these data clearly suggest hyperactive fibrinolysis with increased plasmin generation. 
Collectively, these findings have led to the recent suggestion that elevated plasmin(ogen) 
levels may represent a risk factor for COVID-19 susceptibility.51 
 
Hypoxaemia development secondary to COVID-19-induced ARDS might also activate the 
coagulation cascade and could be important in endothelial dysfunction beyond the capillary 
network; hypoxaemia might also play a role in adjacent small pulmonary vascular 
thrombosis.52,53 Other factors including mechanical ventilation in patients progressing to 
ARDS might contribute to this picture. The role of vascular microrthrombi formation, or 
immunothrombosis, in containment of bacterial infection and spread is well established, but 
its role in viral infection remains less well established.54 Likewise, the role of local 
pulmonary intravascular immunity and its impact on the PIC phenotype is completely 
unknown.55 Nevertheless, adenoviral access to the circulation in an artificial model system 
triggers a MAS-like phenomenon with DIC.56 The role of positive pressure ventilation as a 
factor driving release of viral nucleic acids and proteins across damaged alveolar-endothelial 
cell barriers is another factor that needs consideration as an iatrogenic contributor to 
immunothrombosis and poor outcomes.      
 
Finally, it has also been demonstrated in experimental SARS models that normal aged 
primates have a similar degree of viral replication as younger primates, but that aged primates 
have more pulmonary damage and lower activation of type 1 interferon responsive gene 
pathways.57 At the molecular level, aged mice showed exacerbated innate immune responses 
associated with NF-kB gene pathway activation. including elevated IL-8, and also elevated 
expression of tissue factor—the key extrinisic clotting pathway protein.57 It is well 
established that type 1 interferon responses decrease with age in humans,58 including in 
response to viral infection, but at what age this transition occurs needs better definition.59  
Viral or age-related impairment in type 1 interferon cytokine production appears to be 
associated with a second wave of inflammatory cytokine production and tissue factor 
expression that might substantially contribute to PIC.    
 
 
Implications of PIC 
The role of anti-coagulation in the setting of COVID-19 PIC is of considerable interest.  
Expert recommendations for the use of anti-coagulants have already been published, 
reflecting the recognition of clotting dysregulation.60 The potential relevance of anti-
cardiolipin antibodies in the COVID-19 critical care setting is also recognised but is of 
uncertain significance.61 However, some data are available, mostly derived from prospective 
non-randomised cohort studies. In a study of nearly 450 COVID-19 cases, low molecular 
weight heparin (mostly used in prophylactic rather than therapeutic doses) did not confer an 
overall survival advantage but was associated with improved survival in the group with a 
high sepsis induced coagulopathy (SIC) score and also in those with D-dimer concentrations 
more than 6 times the upper limit of normal.45  The role and timing of anticoagulation in this 
extensive virus-related immunothrombosis, especially where pulmonary haemorrhaging 
occurs, needs very careful consideration. I  DIC, thrombosis and bleeding may occur 
simultaneously, and the same scenario appears to also arise in PIC (Figure 3).   
 
Given the MAS-like pathology of COVID-19 pneumonia, the question arises whether anti-
cytokine therapy will ameliorate the diffuse immunothrombosis process associated with 
severe cases. In the translational setting, the use of the IL-1く blocker canakinumab is 
associated with a decreased risk of all-cause cardiovascular mortality,62 w h an increased 
benefit in patients with the most dramatic reductions in serum IL-6.63  Unlike in low grade 
arterial inflammation in the absence of overt infection, it remains to be seen whether the 
severe COVID-19-associated MAS with PIC will be successfully targeted using these 
strategies, but ongoing viral infection might represent a major hurdle.17 R cently it has also 
emerged that the the coagulation and immune systems are directly linked via thrombin 
cleavage of IL-1 from macrophages and platelets. This novel mechanism is of special 
interest with regard to anakinra, which blocks both the IL-1g and IL-1く pathways, whereas 
monoclonal antibodies such as canakinumab selectively block IL-1く.64   
 
The most critical question is whether the emergent early activation of coagulopathy and 
fibrinolysis in patients with COVID-19 pneumonia is purely due to an appropriate immune 
response to the virus, or whether there is a degree of excessive inflammation that could be 
targeted to help prevent PIC progression. The potential survival advantage of drugs pioneered 
to treat inflammatory and hyper-inflammatory states needs to be viewed through the lens of 
severe diffuse pulmonary immunothrombosis. The combination of immunomodulatory and 
anti-coagulant strategies in patients with high D-dimer concentrations and evidence of 
myocardial stress warrants especially close attention. The use of JAK pathway inhibition 
needs careful scrutiny given the association between JAK inhibitors and thromboembolic 
disease.   
 
Some bleeding complications outside of the lung have been described in patients with 
COVID-19. This is perhaps unsurprising in the minority of PIC cases that progress to 
systemic DIC. Reports of acute necrotising encephalopathy, which is associated with 
haemorrhage, are emerging.65 However, this rare condition is well recognised in association 
with viral infections in general.66 Given that ACE2 is expressed on endothelial cells, the 
notion of thrombosis outside PIC or DIC needs further consideration.    
 
This PIC model has implications for understanding cardiovascular mortality in the current 
pandemic. It shifts the focus away from COVID-19-related myocarditis or coronary vascular 
involvement secondary to viral infection of ACE2-expressing myocytes or endothelial cells, 
with cardiac injury and toward a scenario of multisite pulmonary vascular thrombosis with 
progressive myocardial ischaemia. The immunthrombotic pathology that evolves over several 
days will more likely manifest in patients with underlying cardiovascular risk factors such as 
obesity, hypertension, and type 2 diabetes, and will be compounded by the cardiac ischaemia 
that accompanies ARDS development. Cardiovascular mortality is significantly higher in 
men than women aged 30 to 64 years in many different populations.67 These well known risk 
factors might also account for racial differences in COVID-19 mortality 68,69. The COVID-19 
pandemic with profound immunological changes that constitute a pulmonary MAS-like 
picture is revealing a large burden of subclinical cardiovascular disease in predisposed 
subjects by slowly triggering an extensive pulmonary immunothrombosis. Our model offers a 
different and more robust alternative to the proposed impact of medications on ACE2 
expression with increased viral infectivity.70 It is also important to determine to what degree 
COVID-19-mediated diffuse alveolar damage with ARDS development in the absence of 
coagulopathy may also contribute to outcomes since emerging post-mortem reports do not 
report this pathology in all cases. 
 
Finally, diffuse PIC is not unique to the MAS-like pattern of inflammation. Diffuse alveolar 
infection, activation of innate immune mechanisms, including dysregulation of ACE2 protein 
expression, and marked adaptive anti-viral immune responses could contribute to extensive 
pulmonary immunothrombosis without a clinically evident MAS (Table 3). Will this translate 
into differential efficacy, if any, of immunosuppressive therapy between the MAS-like 
subgroup and those without MAS?  Ultimately, the tropism of COVID-19 for type II 
pneumocytes, along with evidence for extensive microvascular thrombosis during a global 
pandemic in subjects without natural immunity points towards an explanation for the 
increased cardiovascular mortality following respiratory infection that has been recognised 
for some time in other settings. We believe that this PIC, or pulmonary immunovascular 
coagulopathy, represents the best explanation for the COVID-19 pneumonia risk factors for 
poor survival including cardiovascular disease in the present scenario where there is little 
evidence for systemic viraemia in early disease39.   
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Table 1-Differences and Similarities Between DIC and PIC 
 
Clinical Features Disseminated Intravascular 
Coagulation (DIC) linked to 
HLH/MAS 
Pulmonary Intravascular 
Coagulopathy (PIC) linked 
to COVID-19 
Onset Acute Subacute 
Hepatosplenomegaly +++  
Adenopathy ++  
Pulmonary Involvement 50% 100% 
Thrombosis Multi-organ clotting Mainly lung 
(Occasional central nervous 
system and peripheral 
thrombosis reported- related 
to DIC evolution?) 
Bleeding Generalised Intrapulmonary micro-
haemorrhage 
Active Infection 
Considerations 
Yes- usually for primary HLH 
 
Secondary HLH may not have 
driving infection 
Thought to be ongoing 
alveolar infection 
Laboratory Parameters   
Liver Function Raised Transaminase +++ 
 
Decreased synthetic function 
including fibrinogen and other 
clotting factors 
+/- 
 
Preservation of liver synthetic 
function 
Anaemia +++ - 
Thrombocytopenia +++ Normal/low 
Immune Cell Cytopenia ++ No- but lymphopenia a 
feature of COVID-19 in 
general 
Creatanine Kinase + (skeletal and cardiac origin) + (worse prognosis) 
Troponin-T + ++ with higher levels 
associated with worse 
outcome 
Haemophagocytosis Generalised to marrow, liver 
and other sites detectable in 
80%+ 
Occasional intrapulmonary 
and regional lymph node 
haemophagocytosis reported 
 
Evolution  
 
DIC secondary to MAS 
PIC may evolve into DIC  
 
PIC may occur without MAS 
Coagulation & Immunology   
Elevated PT/ APTT +++ / +++ +/normal 
Fibrinogen levels Decreased Normal/slight increase 
FDPs/D-Dimer Increased Increased 
CRP Elevated Elevated 
Ferritin Elevation +++ Elevated 
Hypercytokinaemia +++ ++ 
Table 2- Cardiovascular Disease, Myocarditis and Infection 
 
 
 Findings Ref. 
Cardiac Injury not 
specific to COVID-19 
Cardiac injury in 60%+ with Avian Influenza (H7N9) 
suggesting that cardiac disease linked to infection. 
 
Also linked to history of cardiovascular disease but not male 
sex or diabetes (Note myocarditis well documented with 
influenza in other studies summarised below) 
71 
 
pandemic (H1N1) 2009 virus  
46% Cardiac Injury 
Mean age 34 
Female more common than male 
Presumed Myocarditis- No histology/ No post mortem data 
 
72 
 
COVID-19 Viral Access 
to Heart 
No Viraemia in 9 cases in COVID-19 39 
 
“RNAemia in only 15%” 
Cardiac injury linked to ICU admission and not RNAaemia 
 
38 
Endothelial cells Express ACE2 but cytopathic changes that are seen in 
pneumocytes not reported 
 
37 
Cardiac Myocytes in 
Human 
With SARS no cytopathic change  
Lack of SARS viral protein detection 
34 
Community Acquired 
pneumonia 
Bronchopneumonia 
Increased risk of cardiovascular death 18,19  
Other factors linked to 
cardiac Pathology 
Older age, Male sex, Hypertension, Obesity, Diabetes 
Hypoxia from ARDS development 
Emergent DIC late in COVID-19 disease 
 
Viral Myocarditis H1N1 Influenza A Virus. 
Rare link to Fulminant Myocarditis Reported 
 
73 
Viral Myocarditis 47 Cases of Fatal Influenza Virus,  
Children/ Female predominant 
Myocarditis deemed to be cause of death in 5 cases 
74 
 
 
 
 
 
 
 
 
 
 
Table 3- Immune Factors contributing to Pulmonary Intravascular Coagulopathy 
 
 Diffuse alveolar damage and inflammation 
 
 Diffuse interstitial inflammation 
 
 Extensive pulmonary macrophage activation “MAS-like” 
 
   Dysregulation of pulmonary innate immune e.g. ACE2 receptor expression 
downregulation? 
 Adaptive Immune Responses to COVID-19 
 “Inflammaging”- activation of innate immunity with greater age 
 
 Age related coagulation cascade changes 
 
  Mechanical Ventilation forcing viral immunostimulatory molecules into micro-vasculature 
increasing the propensity towards immunothrombosis 
 
 
 
 
 
 
Figure 1 
 
 
 
 
 
 
 
 
 
 
 Early MAS Picture  Early COVID-19 Picture 
Clinical Hepatosplenomegaly, 
lymphadenopathy 
Pneumonia 
Cardiac Usually Normal Raised Troponin-T and Brain 
Natriuretic Peptide 
Blood Anaemia, low platelets Normal 
Clotting Low Fibrinogen/ high FDPs Normal fibrinogen/High FDPs 
Inflammatory 
Markers 
CPR/ESR Elevated CPR/ESR Elevated 
Bleeding Diffuse clotting and bleeding Clotting and haemorrhage 
confined to pulmonary vasculature 
Immunotherapy Treat Cause e.g. EBV 
 
Suppression of inflammation 
No effective anti-viral 
therapy 
Inflammation Suppression? 
Anti-
Coagulation 
Suppression of inflammation Role of anti-coagulation? 
Evolution  May evolve into DIC 
Legend for Figure 1  
Figure 1A. Secondary HLH/MAS is associated with organomegaly, thrombocytopenia and 
haemophagocytosis and disseminated intravascular coagulation (DIC) with pulmonary 
involvement in half the cases75. Activation of bone marrow, lymphoid organ, hepatic Kupffer 
cells and circulating mononuclear cells leads to a severe consumptive coagulopathy with low 
fibrinongen levels and increased fibrinogen degradation. In addition, liver dysfunction 
exacerbates the consumptive coagulopathy. A rapid onset DIC pattern with 
hyperferritinaemia reflecting generalised haemophagocytosis with erythrocyte degradation, 
sequestration and export with diffuse clotting and bleeding.  
Figure 1B.  Pulmonary involvement without generalised lymphoid organ hyperplasia is 
typical of COVID-19 pneumonia. Haemophagocytosis, albeit intrapulmonary has also been 
reported in coronavirus family infection13. But in the early stages the systemic coagulopathy 
is not a feature. Such intrapulmonary haemophagocytosis and that in regional nodes indicates  
activated macrophage mediated removal of extravascular red blood cells secondary to 
vascular injury.   A DIC picture may also develop late in the course of COVID-19 pneumonia 
in cases with ARDS development.      
A 
 B 
Figure 2 
 
 
 
 
 
Legend for Figure 2 
Figure 2A. Coronavirus family members gain access to the lungs via the ACE-2 receptor that 
is expressed most abundantly on a subpopulation of type II pneumocytes.   The shaded boxes 
on the left and right indicate the much greater capability for immunothrombosis given the 
alveolar tropism for COVID-19. 
Figure 2B. Segmental bronchopneumonia including bacterial and influenza more typically 
has a different lung distribution, with prominent bronchial tree involvement including 
haemorrhagic destruction of trachea and large airways74 nd generally more patchy alveolar 
network disease.  As shown in Figure 2B there may be larger areas with normal perfusion.  
The slow evolution of COVID-19 infection with alveolar hypoxia and micro thrombosis may 
result in pulmonary arterial hypertension and the cardiac picture that mostly occurs with 
hypoxaemia and raised D-dimers.   The scale of alveolar and microvascular inflammation 
rather than systemic viral infection per se determines the cardiovascular pattern of disease.  
Of course segmental bronchopneumonia could results in a degree of immunothrombosis 
sufficient to cause a cardiac event especially in older subjects with known or silent cardiac 
disease. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 
 
 
Legend for Figure 3 
Scheme showing how extensive COVID-19 lung involvement with large anatomical 
interfacing between infected type II pneumocytes, extensive interstitial immunocyte MAS-
like activation and the extensive pulmonary microvascular network, triggers diffuse 
pulmonary bed extrinsic inflammation with immunothrombosis leading to a microthrombotic 
immunopathology that leads to right ventricular stress and contributes to mortality.    
Diffuse type II pneumocyte centric pathology with extension into the intestituim leads to 
extensive pulmonary macrophage recruitment and activation leading to a local MAS-like 
picture.   Pro-inflammatory and pro-coagulants gain access to the capillary network (lower 
circle).   The low pressure nature of the vascular system and thin vessel walls in and proximal 
to the alveolar network triggers immunothrombosis by a variety of mechanisms including 
local elevations in pro-inflammatory cytokines, vessel wall tissue damage with tissue factor 
production and direct injury to small vessels.   Vigorous fibrinolytic activity (detected early 
by D-dimer elevation) may not keep check with the extensive microthrombi formation and 
lead to the evolution of COVID-19 inflammation driven pulmonary infarction, 
haemorrhaging and pulmonary intravascular coagulopathy induced pulmonary hypertension.   
Risk factors for cardiovascular disease may thus increase the likelihood of death in severe 
COVID-19 inflammation. 
 
 
 
 
 
 
